Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

The Australian reports on the ethics approval for Race's RC220 bisantrene Phase 1 clinical trial, featuring an interview with Race's Executive Chair Dr Peter Smith who discussed in-depth bisantrene's clinical history, the structure of the Phase 1 clinical trial, and what the investors can expect next. 

Watch the interview below. Access the full report via this link. 

The Australian: Race Oncology gets ethics nod for Phase I trial in solid tumour patients